photodynamic therapySmall cell lung cancer (SCLC)SCLCPROTAC
…ed locally at the tumor site to penetrate the tumor and enhance photodynamic therapy (PDT), thus precisely induced bromodomain and extraterminal pro…
7,227articles mentioning treatments
16,644treatment mentions
4,719distinct treatments extracted
0%of mentions human-reviewed
All extracted treatments
Showing 2,461–2,520 of 4,719, ordered by supporting articles. Choose a treatment to see its evidence.
Neoadjuvant strategies1Neoadjuvant/perioperative chemoimmunotherapy1Nerve blockade1Nerve catheter infusions1Neurodegeneration1Neurovascular radiotherapy1Non-pharmacological measures1Non-platinum chemotherapy1Nursing Therapeutics1O2D1OLR1OPAT1ORIF1OST1OXT replacement therapy1Obturator nerve block1Ocular-realignment surgery1Oncology treatment1Oncolytic virus (OV) therapy1Oncolytic virus immunotherapy1Opioid agonist treatment (OAT)1Opioid analgesia1Opioids1Oral corticosteroid therapy1Oral iron supplementation1Orofacial Myofunctional Therapy1P/D1PA1PAH-specific treatment1PAUSe1PBMT1PBO1PCM-ESD1PCN1PCNL1PD-1 blockade monotherapy1PD-1 checkpoint blockade1PD-1 therapy1PD-1/PD-L1 blockade1PD-L1 blockade1PDT1PED Flex1PH-specific therapy1PHEA1PI-based regimen1PIM1PP4M1PPI1PPI therapy1PRAME-targeting T cell therapy1PRN breakthrough analgesia1PROTAC1PT1PT-CIP1PTK1PVB1PVI1Paediatric liver transplantation1Paediatric thrombectomy1Pain and symptom management1
Articles mentioning treatments
7,227 articles · page 492 of 603CAR-T therapiessolid tumorshematologic malignanciesCAR-T
…Background Several CAR-T therapies have been approved for hematologic malignancies. However despit…
Cellular immunotherapieshematological malignanciesTravirtideProtransduzin-BVectofusin-1
…Background Cellular immunotherapies using genetically reprogrammed immune cells, such as T-lymphocy…
immunotherapiesSolid tumorsovarian cancersbreasthematologic malignancies
…y in the U.S. Despite advances in surgery, targeted agents, and immunotherapies, durable responses remain limited. Both ex vivo and in vivo chi…
Chimeric antigen receptor T (CAR-T) cell therapieshematological cancersolid tumorsgraft-versus-host diseasesolid cancerxenograft mouse models
…Background Chimeric antigen receptor T (CAR-T) cell therapies are a form of adoptive cell therapy that has shown promising cl…
83.5%
anti-cancer interventionsThe Ohio State UniversityPancreatic Ductal Adenocarcinoma (PDAC)Ohio State UniversityAssociation for Assessment and Accreditation of Laboratory Animal Care International
…systemic inflammation, cachexia reduces the efficacy of various anti-cancer interventions and enhances the morbidity of PDAC. Recent research suggests th…
Adoptive cell therapy (ACT)University of Pittsburghcancers
…Background Adoptive cell therapy (ACT), in which T cells are isolated from a patient, expanded to high…
chimeric antigen receptor T (CART) cell therapyMayo Clinic Division of HematologyMayo Clinic Center for Individualized Medicine4-1BBMayo Clinic
…Background Despite the high initial responses to chimeric antigen receptor T (CART) cell therapy, most patients relapse within the first 1-2 years. Patient-deri…
CAR T cell therapysolid tumorsDIPGpediatric brain tumorshematologic malignanciespediatric high-grade gliomasdiffuse intrinsic pontine glioma (DIPG)NLVIL13Rα2-targeting 41BB-based CARNLVPMVATV+2 more
…Background CAR T cell therapy has transformed the treatment landscape for hematologic maligna…
immunotherapyLung cancer
…lecular disparities may impact access to targeted therapies and immunotherapy. Although prior studies report variations in genetic alteration…
chimeric antigen receptor (CAR) T-cell therapyDiffuse Intrinsic Pontine GliomaDIPG
… brain tumor with median survival of less than 12 months. While chimeric antigen receptor (CAR) T-cell therapy shows promise, its efficacy in DIPG is limited by a profoundly …
CAR-T cell therapyNeuroblastomaGD2BBDAP12University of Wisconsin-MadisonGD2BBζ
…astoma cells has provided a target for immunotherapy, including CAR-T cell therapy. Recently published work using anti-GD2 CAR-T cells in relapsed…